Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04634877
Title	Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
Recruitment	Active, not recruiting
Gender	female
Phase	Phase III
Variant Requirements	Yes
Sponsors	Merck Sharp & Dohme Corp.
Indications	endometrial carcinoma uterine carcinosarcoma
Therapies	Carboplatin + Paclitaxel Cisplatin + Paclitaxel Carboplatin + Docetaxel Cisplatin + Paclitaxel + Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Docetaxel + Pembrolizumab Cisplatin + Docetaxel Carboplatin + Docetaxel + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| POL \| NOR \| ITA \| ISR \| GRC \| GBR \| FRA \| FIN \| ESP \| DNK \| DEU \| CZE \| CAN \| BEL \| AUT \| ARG